Emerging nonsteroidal mineralocorticoid receptor antagonists with greater selectivity and improved safety profiles may offer the potential to slow the decline in kidney function and mitigate cardiovascular risk in ADPKD. This evidence concerns the gene NR3C2 and autosomal dominant polycystic kidney disease.